{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:58:36Z","timestamp":1790798316897,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T00:00:00Z","timestamp":1454371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2016,6]]},"abstract":"Summary<\/jats:title>Background<\/jats:title>Treatment of melasma remains a challenge and involves multistep approach. Diacetyl boldine (DAB<\/jats:styled-content>) stabilizes tyrosinase in its inactive form while TGF<\/jats:styled-content>\u2010\u03b2<\/jats:italic>1 biomimetic oligopeptide\u201068 inhibits tyrosinase activity.<\/jats:p><\/jats:sec>Aims<\/jats:title>(1) to study the efficacy and safety of the combination use of two formulae containing two principal ingredients: DAB<\/jats:styled-content> and TGF<\/jats:styled-content>\u2010\u03b2<\/jats:italic>1 biomimetic oligopeptide\u201068 on facial melasma, and (2) to compare their efficacy with 2% and 4% hydroquinone cream (HQ<\/jats:styled-content>) on sun\u2010protected normal skin.<\/jats:p><\/jats:sec>Methods<\/jats:title>A randomized, double\u2010blind, 12\u2010week comparative study of pre\u2010\/post\u2010treatment was conducted in 40 females. Melasma was evaluated by manual MASI<\/jats:styled-content> score and MASI<\/jats:styled-content> score with instrumentally graded darkness at baseline, 6th week, and 12th week. The author also compared their effect with HQ<\/jats:styled-content> on the arms, assessed their safety profile throughout the study.<\/jats:p><\/jats:sec>Results<\/jats:title>Thirty\u2010eight subjects have completed the study. Their melasma showed improvement at the 6th week and 12th week as compared with baseline (P<\/jats:italic> < 0.05). None developed severe reaction. Most subjects had temporary, mild skin reaction. About 2.6% of subjects graded themselves markedly improved, 76.3% moderately improved, and 21.1% slightly improved. Each formula showed either more efficacy or exerted faster action on pigment reduction than HQ<\/jats:styled-content>.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Combination of DAB<\/jats:styled-content> serum at night and DAB<\/jats:styled-content>\/TGF<\/jats:styled-content>\u2010\u03b2<\/jats:italic>1 biomimetic oligopeptide\u201068\/sunscreen cream in the morning and at noon was effective and safe for facial melasma. They were superior to HQ<\/jats:styled-content> in pigment reduction.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.12201","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T07:28:37Z","timestamp":1454398117000},"page":"131-144","source":"Crossref","is-referenced-by-count":15,"title":["Combined use of two formulations containing diacetyl boldine, TGF<\/scp>\u2010\u03b2<\/i>1 biomimetic oligopeptide\u201068 with other hypopigmenting\/exfoliating agents and sunscreen provides effective and convenient treatment for facial melasma. Either is equal to or is better than 4% hydroquinone on normal skin"],"prefix":"10.1111","volume":"15","author":[{"given":"Walai\u2010orn","family":"Pratchyapurit","sequence":"first","affiliation":[{"name":"Department of Medical Services Institute of Dermatology Rajathevi Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,2]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"3","article-title":"Di\u2010acetyl\u2010nor\u2010aporphines: novel molecules and novel mechanism to inhibit melanogenesis","volume":"130","author":"Mas\u2010Chamberlin C","year":"2004","journal-title":"S\u00d6FW\u2010Journal"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/120347540200600308"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.1997.9"},{"key":"e_1_2_8_5_1","first-page":"772","volume-title":"Fitzpatrick's Dermatology in General Medicine","author":"Park HY","year":"2012"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052166"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddmec.2008.02.001"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2003.10.023"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.01219"},{"key":"e_1_2_8_10_1","first-page":"153","article-title":"Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening","volume":"86","author":"Draelos ZD","year":"2010","journal-title":"Cutis"},{"key":"e_1_2_8_11_1","unstructured":"Lucas Meyer Cosmetics (formerly Unipex Innovations).\u00df\u2010White\u2122Technical file. [online] n.d. [cited 2015 March 13]:[33 screens] Available from URL:http:\/\/www.lanopearlexport.com\/downloads\/research\/B-White.pdf"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2008.8"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0749.1998.tb00494.x"},{"key":"e_1_2_8_14_1","first-page":"59","article-title":"Melanogenesis inhibitor from paper mulberry","volume":"112","author":"Dong\u2010II J","year":"1997","journal-title":"Cosmet Toiletries"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1473-2165.2008.00387.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2007.04.012"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.12.s2.7.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000088509"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07590.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690060057005"},{"key":"e_1_2_8_21_1","first-page":"868","article-title":"Topical isotretinoin for melasma in Thai patients: a vehicle\u2010controlled clinical trial","volume":"82","author":"Leenutaphong V","year":"1999","journal-title":"J Med Assoc Thai"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0846.2010.00489.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2009.00425.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2007.01138.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546630903214167"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.12138"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjocd.12201","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjocd.12201","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.12201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T07:57:18Z","timestamp":1696492638000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.12201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/jocd.12201"],"URL":"https:\/\/doi.org\/10.1111\/jocd.12201","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,2]]}}}